The clinical and biological features, and outcomes of children with AML receiving at least one induction cycle of LDC/G-CSF were compare with those receiving standard-dose chemotherapy (SDC), to investigate whether LDC could achieve similar clinical efficacy as SDC. This evidence concerns the gene CSF3 and acute myeloid leukemia.